QuatRx Initiates Second Phase 3 Study Of Ophena(TM) (Ospemifene Tablets) In Women With Postmenopausal Vaginal Syndrome

QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, announced that it has initiated a second Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company’s estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

More: continued here

Filed under: Clinical Trials on September 8th, 2008